EyePoint Pharmaceuticals Inc (FRA:PV3B)
€ 7.932 0.038 (0.48%) Market Cap: 409.05 Mil Enterprise Value: 136.42 Mil PE Ratio: 0 PB Ratio: 1.69 GF Score: 61/100

EyePoint Pharmaceuticals Inc to Host Virtual Key Opinion Leader Transcript

Nov 09, 2023 / 01:00PM GMT
Release Date Price: €6.4 (-9.22%)
Operator

Ladies and gentlemen, thank you for standing by. Welcome to the EyePoint Pharmaceuticals Virtual Key Opinion Leader event. (Operator Instructions). Please be advised that today's conference is being recorded.

I would now like to turn the conference over to Pharmaceuticals President and Chief Executive Officer; Dr. Jay Duker. Please go ahead.

Jay S. Duker
EyePoint Pharmaceuticals, Inc. - President, CEO & Director

Good morning to everyone, and thank you so much for joining EyePoint Pharmaceuticals Virtual KOL event. I am Jay Duker, President and CEO of EyePoint Pharmaceuticals. Before we begin with our program, I want to remind you that various remarks we will make today constitute forward-looking statements. These include statements about our future expectations, clinical developments and regulatory matters and time lines, the potential success of our products and product candidates, financial projections and our plans and prospects. Actual results may differ materially from those indicated by these forward-looking statements. Please refer to our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot